Evidence map›Paper›PMID 35483990›Full record

ReviewTrends in biotechnology2022

In situ bioprinting: intraoperative implementation of regenerative medicine.

Mohamadmahdi Samandari, Azadeh Mostafavi, Jacob Quint, Adnan Memić, Ali Tamayol

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Immune-Responsive Bioinks Enable Vision-GuidedAdvanced functional materials · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Sprayable Hydrogel Dressings in Wound-Healing Applications.Bioengineering (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamadmahdi SamandariDepartment of Biomedical Engineering, University of Connecticut, Farmington, CT, USA.
Azadeh MostafaviDepartment of Mechanical and Materials Engineering, University of Nebraska, Lincoln, Lincoln, NE, USA.
Jacob QuintDepartment of Biomedical Engineering, University of Connecticut, Farmington, CT, USA.
Adnan MemićCenter of Nanotechnology, King Abdulaziz University, Jeddah, Saudi Arabia.
Ali TamayolDepartment of Biomedical Engineering, University of Connecticut, Farmington, CT, USA; Department of Mechanical and Materials Engineering, University of Nebraska, Lincoln, Lincoln, NE, USA. Electronic address: atamayol@uchc.edu.

Funding

Suturable bioprinted vascularized muscle constructs for treatment of skeletal muscle lossR01AR077132 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON, TAMAYOL, ALI · 2021 to 2025
$2.6M
Microengineered scaffolds carrying patient-specific cells and growth factors for treatment of volumetric muscle lossR01AR073822 · NIAMS · UNIVERSITY OF NEBRASKA LINCOLN · PI TAMAYOL, ALI · 2018 to 2022
$1.8M
Multifunctional dressing for treatment of diabetic woundsR01GM126831 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI DOKMECI, MEHMET REMZI, TAMAYOL, ALI · 2018 to 2021
$1.3M
Regenerative Engineering of Musculoskeletal Tissues- a Convergence Doctoral Training ProgramT32AR079114 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LAURENCIN, CATO T. · 2021 to 2025
$1.1M
NIAMS NIH HHS R01 AR073822NIAMS NIH HHS R01 AR077132NIAMS NIH HHS T32 AR079114NIGMS NIH HHS R01 GM126831
6 · The paper itself

Abstract

Bioprinting has emerged as a strong tool for devising regenerative therapies to address unmet medical needs. However, the translation of conventional in vitro bioprinting approaches is partially hindered due to challenges associated with the fabrication and implantation of irregularly shaped scaffolds and their limited accessibility for immediate treatment by healthcare providers. An alternative strategy that has recently drawn significant attention is to directly print the bioink into the patient's body, so-called 'in situ bioprinting'. The bioprinting strategy and the associated bioink need to be specifically designed for in situ bioprinting to meet the particular requirements of direct deposition in vivo. In this review, we discuss the developed in situ bioprinting strategies, their advantages, challenges, and possible future improvements.

Indexed as

BioprintingHumansPrinting, Three-DimensionalRegenerative MedicineTissue EngineeringTissue Scaffoldsbioinksbioprintinghandheld printersin situ printingrobotic bioprinters

Identifiers

PMID35483990
PMCPMC9481658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.